Prediction of the Repeat Domain Structures and Impact of Parkinsonism-Associated Variations on Structure and Function of all Functional Domains of Leucine-Rich Repeat Kinase 2 (LRRK2)

Human Mutation

Volumn 35, Issue 4, 2014, Pages 395-412

  Mills, Ryan D ^a   Mulhern, Terrence D ^a   Liu, Fei ^c   Culvenor, Janetta G ^b   Cheng, Heung Chin ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MACQUARIE UNIVERSITY   (Australia)

Author keywords

LRRK2; Neurotoxicity; Parkinson disease; Phosphorylation; Protein interactions; Protein kinase

Indexed keywords

BACTERIAL PROTEIN; LEUCINE RICH REPEAT KINASE 2; PROTEIN ROCO4; PROTOZOAL PROTEIN; RAB FAMILY PROTEIN; UNCLASSIFIED DRUG; PROTEIN BINDING; PROTEIN SERINE THREONINE KINASE;

CATALYSIS; CHLOROBIUM; CHLOROBIUM TEPIDUM; CONCEPTUAL FRAMEWORK; DICTYOSTELIUM DISCOIDEUM; ENZYME STRUCTURE; HUMAN; NONHUMAN; PARKINSONISM; PREDICTION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; REVIEW; ANIMAL; BINDING SITE; CHEMICAL STRUCTURE; CHEMISTRY; ENZYMOLOGY; GENETICS; METABOLISM; NUCLEOTIDE SEQUENCE; PARKINSON DISEASE; PROTEIN CONFORMATION; PROTEIN SECONDARY STRUCTURE;

CHLOROBACULUM TEPIDUM; DICTYOSTELIUM DISCOIDEUM;

ANIMALS; BACTERIAL PROTEINS; BINDING SITES; CONSERVED SEQUENCE; HUMANS; MODELS, MOLECULAR; PARKINSON DISEASE; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN STRUCTURE, SECONDARY; PROTEIN-SERINE-THREONINE KINASES; PROTOZOAN PROTEINS;

EID: 84896111174     PISSN: 10597794     EISSN: 10981004     Source Type: Journal    
DOI: 10.1002/humu.22515     Document Type: Review

References (159)

1. Agola JO, Hong L, Surviladze Z, Ursu O, Waller A, Strouse JJ, Simpson DS, Schroeder CE, Oprea TI, Golden JE, Aube J, Buranda T, et al. 2012. A competitive nucleotide binding inhibitor: in vitro characterization of Rab7 GTPase inhibition. ACS Chem Biol 7:1095-1108.
2. Alberts AS. 2001. Identification of a carboxyl-terminal diaphanous-related formin homology protein autoregulatory domain. J Biol Chem 276:2824-2830.
3. Anand VS, Reichling LJ, Lipinski K, Stochaj W, Duan W, Kelleher K, Pungaliya P, Brown EL, Reinhart PH, Somberg R, Hirst, WD, Riddle, SM, et al. 2009. Investigation of leucine-rich repeat kinase 2: enzymological properties and novel assays. FEBS J 276:466-478.
4. Andrade MA, Petosa C, O'Donoghue SI, Müller CW, Bork P. 2001. Comparison of ARM and HEAT protein repeats. J Mol Biol 309:1-18.
5. Bauer B, Mirey G, Vetter IR, García-Ranea JA, Valencia A, Wittinghofer A, Camonis JH, Cool RH. 1999. Effector recognition by the small GTP-binding proteins Ras and Ral. J Biol Chem 274:17763-17770.
6. Bella J, Hindle KL, McEwan PA, Lovell SC. 2008. The leucine-rich repeat structure. Cell Mol Life Sci 65:2307-2333.
7. Berg D, Schweitzer K, Leitner P, Zimprich A, Lichtner P, Belcredi P, Brussel T, Schulte C, Maass S, Nagele T. 2005. Type and frequency of mutations in the LRRK2 gene in familial and sporadic Parkinson's disease. Brain 128:3000-3011.
8. Berger Z, Smith KA, Lavoie MJ. 2010. Membrane localization of LRRK2 is associated with increased formation of the highly active LRRK2 dimer and changes in its phosphorylation. Biochemistry 49:5511-5523.
9. Biosa A, Trancikova A, Civiero L, Glauser L, Bubacco L, Greggio E, Moore DJ. 2013. GTPase activity regulates kinase activity and cellular phenotypes of Parkinson's disease-associated LRRK2. Hum Mol Genet 22:1140-1156.
10. Blanco S, Santos C, Lazo PA. 2007. Vaccinia-related kinase 2 modulates the stress response to hypoxia mediated by TAK1. Mol Cell Biol 27:7273-7283.
11. Bosgraaf L, Van Haastert PJ. 2003. Roc, a Ras/GTPase domain in complex proteins. Biochim Biophys Acta 1643:5-10.
12. Chen CY, Weng YH, Chien KY, Lin KJ, Yeh TH, Cheng YP, Lu CS, Wang HL. 2012. (G2019S) LRRK2 activates MKK4-JNK pathway and causes degeneration of SN dopaminergic neurons in a transgenic mouse model of PD. Cell Death Differ 19:1623-1633.
13. Cheng HC, Qi RZ, Paudel H, Zhu HJ. 2011. Regulation and function of protein kinases and phosphatases. Enzyme Res 2011:794089.
14. Choe J, Kelker MS, Wilson IA. 2005. Crystal structure of human toll-like receptor 3 (TLR3) ectodomain. Science 309:581-585.
15. Choi HJ, Weis WI. 2005. Structure of the armadillo repeat domain of plakophilin 1. J Mol Biol 346:367-376.
16. Civiero L, Vancraenenbroeck R, Belluzzi E, Beilina A, Lobbestael E, Reyniers L, Gao F, Micetic I, De Maeyer M, Bubacco L, Greggio E, Taymans, JM. 2012. Biochemical characterization of highly purified leucine-rich repeat kinases 1 and 2 demonstrates formation of homodimers. PLoS One 7:e43472.
17. Clegg NJ, Whitehead IP, Williams JA, Spiegelman GB, Grigliatti TA. 1993. A developmental and molecular analysis of Cdc2 mutations in Drosophila melanogaster. Genome 36:676-685.
18. Conti E, Kuriyan J. 2000. Crystallographic analysis of the specific yet versatile recognition of distinct nuclear localization signals by karyopherin alpha. Structure 8:329-338.
19. Cookson MR. 2010. The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease. Nat Rev Neurosci 11:791-797.
20. Covy JP, Giasson BI. 2009. Identification of compounds that inhibit the kinase activity of leucine-rich repeat kinase 2. Biochem Biophys Res Commun 378:473-477.
21. Cuny GD. 2012. Neurodegenerative diseases: challenges and opportunities. Fut Med Chem 4:1647-1649.
22. Daniëls V, Baekelandt V, Taymans JM. 2011a. On the road to leucine-rich repeat kinase 2 signalling: evidence from cellular and in vivo studies. Neurosignals 19:1-15.
23. Daniëls V, Vancraenenbroeck R, Law BM, Greggio E, Lobbestael E, Gao F, De Maeyer M, Cookson MR, Harvey K, Baekelandt V, Taymans, JM. 2011b. Insight into the mode of action of the LRRK2 Y1699C pathogenic mutant. J Neurochem 116:304-315.
24. Dar AC, Shokat KM. 2011. The evolution of protein kinase inhibitors from antagonists to agonists of cellular signaling. Annu Rev Biochem 80:769-795.
25. Deng J, Lewis PA, Greggio E, Sluch E, Beilina A, Cookson MR. 2008a. Structure of the ROC domain from the Parkinson's disease-associated leucine-rich repeat kinase 2 reveals a dimeric GTPase. Proc Natl Acad Sci USA 105:1499-1504.
26. Deng J, Lewis PA, Greggio E, Sluch E, Beilina A, Cookson MR. 2008b. Structure of the ROC domain from the Parkinson's disease-associated leucine-rich repeat kinase 2 reveals a dimeric GTPase. Proc Natl Acad Sci USA 105:1499-1504.
27. Di Fonzo A, Rohé CF, Ferreira J, Chien HF, Vacca L, Stocchi F, Guedes L, Fabrizio E, Manfredi M, Vanacore NN Goldwurm S, Breedveld, G, et al. 2005. A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease. Lancet 365:412-415.
28. Di Fonzo A, Wu-Chou YH, Lu CS, van Doeselaar M, Simons EJ, Rohé CF, Chang HC, Chen RS, Weng YH, Vanacore N, Breedveld, G J, Oostra, BA, et al. 2006. A common missense variant in the LRRK2 gene, Gly2385Arg, associated with Parkinson's disease risk in Taiwan. Neurogenetics 7:133-138.
29. Di Matteo A, Federici L, Mattei B, Salvi G, Johnson KA, Savino C, De Lorenzo G, Tsernoglou D, Cervone F. 2003. The crystal structure of polygalacturonase-inhibiting protein (PGIP), a leucine-rich repeat protein involved in plant defense. Proc Natl Acad Sci USA 100:10124-10128.
30. Dzamko N, Deak M, Hentati F, Reith AD, Prescott AR, Alessi DR, Nichols RJ. 2010. Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization. Biochem J 430:405-413.
31. Dzamko N, Inesta-Vaquera F, Zhang J, Xie C, Cai H, Arthur S, Tan L, Choi H, Gray N, Cohen P Pedrioli P, Clark K, et al. 2012. The IkappaB kinase family phosphorylates the Parkinson's disease kinase LRRK2 at Ser935 and Ser910 during Toll-like receptor signaling. PLoS One 7:e39132.
32. Enkhbayar P, Kamiya M, Osaki M, Matsumoto T, Matsushima N. 2004. Structural principles of leucine-rich repeat (LRR) proteins. Proteins 54:394-403.
33. Fernandes H, Franklin E, Recacha R, Houdusse A, Goud B, Khan AR. 2009. Structural aspects of Rab6-effector complexes. Biochem Soc Trans 37:1037-1041.
34. Funayama M, Hasegawa K, Ohta E, Kawashima N, Komiyama M, Kowa H, Tsuji S, Obata F. 2005. An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family. Ann Neurol 57:918-921.
35. Fung HC, Chen CM, Hardy J, Singleton AB, Wu YR. 2006. A common genetic factor for Parkinson disease in ethnic Chinese population in Taiwan. BMC Neurol 6:47.
36. Giesert F, Hofmann A, Burger A, Zerle J, Kloos K, Hafen U, Ernst L, Zhang J, Vogt-Weisenhorn DM, Wurst W. 2013. Expression analysis of lrrk1, lrrk2 and lrrk2 splice variants in mice. PLoS One 8:e63778.
37. Gilsbach BK, Ho FY, Vetter IR, van Haastert PJ, Wittinghofer A, Kortholt A. 2012. Roco kinase structures give insights into the mechanism of Parkinson disease-related leucine-rich-repeat kinase 2 mutations. Proc Natl Acad Sci USA 109:10322-10327.
38. Gloeckner CJ, Boldt K, von Zweydorf F, Helm S, Wiesent L, Sarioglu H, Ueffing M. 2010. Phosphopeptide analysis reveals two discrete clusters of phosphorylation in the N-terminus and the Roc domain of the Parkinson-disease associated protein kinase LRRK2. J Proteome Res 9:1738-1745.
39. Gotthardt K, Weyand M, Kortholt A, Van Haastert PJ, Wittinghofer A. 2008a. Structure of the Roc-COR domain tandem of C. tepidum, a prokaryotic homologue of the human LRRK2 Parkinson kinase. EMBO J 27:2239-2249.
40. Gotthardt K, Weyand M, Kortholt A, Van Haastert PJ, Wittinghofer A. 2008b. Structure of the Roc-COR domain tandem of C. tepidum, a prokaryotic homologue of the human LRRK2 Parkinson kinase. EMBO J 27:2239-2249.
41. Gotthardt K, Weyand M, Kortholt A, Van Haastert PJ, Wittinghofer A. 2008c. Structure of the Roc-COR domain tandem of C. tepidum, a prokaryotic homologue of the human LRRK2 Parkinson kinase. EMBO J 27:2352.
42. Greggio E. 2012. Role of LRRK2 kinase activity in the pathogenesis of Parkinson's disease. Biochem Soc Trans 40:1058-1062.
43. Greggio E, Jain S, Kingsbury A, Bandopadhyay R, Lewis P, Kaganovich A, van der Brug MP, Beilina A, Blackinton J, Thomas KJ Ahmad R, Miller, DW, et al. 2006. Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol Dis 23:329-341.
44. Greggio E, Taymans JM, Zhen EY, Ryder J, Vancraenenbroeck R, Beilina A, Sun P, Deng J, Jaffe H, Baekelandt, Merchant K, Cookson, MR 2009. The Parkinson's disease kinase LRRK2 autophosphorylates its GTPase domain at multiple sites. Biochem Biophys Res Commun 389:449-454.
45. Greggio E, Zambrano I, Kaganovich A, Beilina A, Taymans JM, Daniels V, Lewis P, Jain S, Ding J, Syed A Thomas, KJ, Baekelandt V, et al. 2008a. The Parkinson disease-associated leucine-rich repeat kinase 2 (LRRK2) is a dimer that undergoes intramolecular autophosphorylation. J Biol Chem 283:16906-16914.
46. Guo L, Gandhi PN, Wang W, Petersen RB, Wilson-Delfosse AL, Chen SG. 2007. The Parkinson's disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activity. Exp Cell Res 313:3658-3670.
47. Habig K, Gellhaar S, Heim B, Djuric V, Giesert F, Wurst W, Walter C, Hentrich T, Riess O, Bonin M. 2013. LRRK2 guides the actin cytoskeleton at growth cones together with ARHGEF7 and Tropomyosin 4. Biochim Biophys Acta 1832:2352-2367.
48. Haebig K, Gloeckner CJ, Miralles MG, Gillardon F, Schulte C, Riess O, Ueffing M, Biskup S, Bonin M. 2010. ARHGEF7 (Beta-PIX) acts as guanine nucleotide exchange factor for leucine-rich repeat kinase 2. PLoS One 5:e13762.
49. Hao B, Oehlmann S, Sowa ME, Harper JW, Pavletich NP. 2007. Structure of a Fbw7-Skp1-cyclin E complex: multisite-phosphorylated substrate recognition by SCF ubiquitin ligases. Mol Cell 26:131-143.
50. Higashi S, Moore DJ, Yamamoto R, Minegishi M, Sato K, Togo T, Katsuse O, Uchikado H, Furukawa Y, Hino H Kosaka K, Emson, PC, et al. 2009. Abnormal localization of leucine-rich repeat kinase 2 to the endosomal-lysosomal compartment in lewy body disease. J Neuropathol Exp Neurol 68:994-1005.
51. Hsu CH, Chan D, Greggio E, Saha S, Guillily MD, Ferree A, Raghavan K, Shen GC, Segal L, Ryu H, Cookson, MR, Wolozin, B 2010a. MKK6 binds and regulates expression of Parkinson's disease-related protein LRRK2. J Neurochem 112:1593-1604.
52. Hsu CH, Chan D, Wolozin B. 2010b. LRRK2 and the stress response: interaction with MKKs and JNK-interacting proteins. Neurodegener Dis 7:68-75.
53. Hutti JE, Jarrell ET, Chang JD, Abbott DW, Storz P, Toker A, Cantley LC, Turk BE. 2004. A rapid method for determining protein kinase phosphorylation specificity. Nat Methods 1:27-29.
54. Ishihara L, Gibson RA, Warren L, Amouri R, Lyons K, Wielinski C, Hunter C, Swartz JE, Elango R, Akkari PA, Leppert D, Surh L, et al. 2007. Screening for Lrrk2 G2019S and clinical comparison of Tunisian and North American Caucasian Parkinson's disease families. Mov Disord 22:55-61.
55. Ishiyama N, Lee SH, Liu S, Li GY, Smith MJ, Reichardt LF, Ikura M. 2010. Dynamic and static interactions between p120 catenin and E-cadherin regulate the stability of cell-cell adhesion. Cell 141:117-128.
56. Ito G, Iwatsubo T. 2012. Re-examination of the dimerization state of leucine-rich repeat kinase 2: predominance of the monomeric form. Biochem J 441:987-994.
57. Ito G, Okai T, Fujino G, Takeda K, Ichijo H, Katada T, Iwatsubo T. 2007. GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson's disease. Biochemistry 46:1380-1388.
58. Jaleel M, Nichols RJ, Deak M, Campbell DG, Gillardon F, Knebel A, Alessi DR. 2007. LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity. Biochem J 405:307-317.
59. James NG, Digman MA, Gratton E, Barylko B, Ding X, Albanesi JP, Goldberg MS, Jameson DM. 2012. Number and brightness analysis of LRRK2 oligomerization in live cells. Biophys J 102:L41-L43.
60. Jeffrey PD, Tong L, Pavletich NP. 2000. Structural basis of inhibition of CDK-cyclin complexes by INK4 inhibitors. Genes Dev 14:3115-3125.
61. Jorgensen ND, Peng Y, Ho CC, Rideout HJ, Petrey D, Liu P, Dauer WT. 2009. The WD40 domain is required for LRRK2 neurotoxicity. PLoS One 4:e8463.
62. Kachergus J, Mata IF, Hulihan M, Taylor JP, Lincoln S, Aasly J, Gibson JM, Ross OA, Lynch T, Wiley J Payami H, Nutt J, et al. 2005. Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. Am J Hum Genet 76:672-680.
63. Kamikawaji S, Ito G, Sano T, Iwatsubo T. 2013. Differential effects of familial parkinson mutations in LRRK2 revealed by a systematic analysis of autophosphorylation. Biochemistry 52:6052-6062.
64. Khan NL, Jain S, Lynch JM, Pavese N, Abou-Sleiman P, Holton JL, Healy DG, Gilks WP, Sweeney MG, Ganguly M Gibbons V, Gandhi S, et al. 2005. Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data. Brain 128:2786-2796.
65. Kobe B. 1999. Autoinhibition by an internal nuclear localization signal revealed by the crystal structure of mammalian importin alpha. Nat Struct Biol 6:388-397.
66. Kornev AP, Taylor SS. 2010. Defining the conserved internal architecture of a protein kinase. Biochim Biophys Acta 1804:440-444.
67. Kornev AP, Taylor SS, Ten Eyck LF. 2008. A helix scaffold for the assembly of active protein kinases. Proc Natl Acad Sci USA 105:14377-14382.
68. Lee BD, Shin JH, VanKampen J, Petrucelli L, West AB, Ko HS, Lee YI, Maguire-Zeiss KA, Bowers WJ, Federoff HJ, Dawson, VL, Dawson, TM 2010a. Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease. Nat Med 16:998-1000.
69. Lee S, Liu HP, Lin WY, Guo H, Lu B. 2010b. LRRK2 kinase regulates synaptic morphology through distinct substrates at the presynaptic and postsynaptic compartments of the Drosophila neuromuscular junction. J Neurosci 30:16959-16969.
70. 2+ and calmodulin-dependent protein kinase required for bacterial and fungal symbioses. Science 303:1361-136.
71. Li D, Roberts R. 2001. WD-repeat proteins: structure characteristics, biological function, and their involvement in human diseases. Cell Mol Life Sci 58:2085-2097.
72. Li J, Mahajan A, Tsai MD. 2006. Ankyrin repeat: a unique motif mediating protein-protein interactions. Biochemistry 45:15168-15178.
73. Li X, Moore DJ, Xiong Y, Dawson TM, Dawson VL. 2010a. Reevaluation of phosphorylation sites in the Parkinson disease-associated leucine-rich repeat kinase 2. J Biol Chem 285:29569-29576.
74. Li X, Patel JC, Wang J, Avshalumov MV, Nicholson C, Buxbaum JD, Elder GA, Rice ME, Yue Z. 2010b. Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S. J Neurosci 30:1788-1797.
75. Li X, Wang QJ, Pan N, Lee S, Zhao Y, Chait BT, Yue Z. 2011. Phosphorylation-dependent 14-3-3 binding to LRRK2 is impaired by common mutations of familial Parkinson's disease. PLoS One 6:e17153.
76. Lim SM, Westover KD, Ficarro SB, Harrison RA, Choi HG, Pacold ME, Carrasco M, Hunter J, Kim ND, Xie T, Sim T, Jänne PA, et al. 2014. Therapeutic targeting of oncogenic k-ras by a covalent catalytic site inhibitor. Angew Chem Int Ed Engl 53:199-204.
77. Liu M, Bender SA, Cuny GD, Sherman W, Glicksman M, Ray SS. 2013. Type II kinase inhibitors show an unexpected inhibition mode against Parkinson's disease-linked LRRK2 mutant G2019S. Biochemistry 52:1725-1736.
78. Liu M, Dobson B, Glicksman MA, Yue Z, Stein RL. 2010. Kinetic mechanistic studies of wild-type leucine-rich repeat kinase 2: characterization of the kinase and GTPase activities. Biochemistry 49:2008-2017.
79. Liu M, Kang S, Ray S, Jackson J, Zaitsev AD, Gerber SA, Cuny GD, Glicksman MA. 2012. Kinetic, mechanistic, and structural modeling studies of truncated wild-type leucine-rich repeat kinase 2 and the G2019S mutant. Biochemistry 50: 9399-9408.
80. Liu Z, Wang X, Yu Y, Li X, Wang T, Jiang H, Ren Q, Jiao Y, Sawa A, Moran T, Ross CA, Montell C, et al. 2008. A Drosophila model for LRRK2-linked parkinsonism. Proc Natl Acad Sci USA 105:2693-2698.
81. Lobbestael E, Baekelandt V, Taymans JM. 2012. Phosphorylation of LRRK2: from kinase to substrate. Biochem Soc Trans 40:1102-1110.
82. Lobbestael E, Zhao J, Rudenko IN, Beylina A, Gao F, Wetter J, Beullens M, Bollen M, Cookson MR, Baekelandt V, Nichols RJ, Taymans JM 2013. Identification of protein phosphatase 1 as a regulator of the LRRK2 phosphorylation cycle. Biochem J 456:119-128.
83. Lott K, Cingolani G. 2011. The importin beta binding domain as a master regulator of nucleocytoplasmic transport. Biochim Biophys Acta 1813:1578-1592.
84. Lu B, Zhai Y, Wu C, Pang X, Xu Z, Sun F. 2010. Expression, purification and preliminary biochemical studies of the N-terminal domain of leucine-rich repeat kinase 2. Biochim Biophys Acta 1804:1780-1784.
85. Luzón-Toro B, Rubio de la Torre E, Delgado A, Pérez-Tur J, Hilfiker S. 2007. Mechanistic insight into the dominant mode of the Parkinson's disease-associated G2019S LRRK2 mutation. Hum Mol Genet 16:2031-2039.
86. Macedo MG, Verbaan D, Fang Y, van Rooden SM, Visser M, Anar B, Uras A, Groen JL, Rizzu P, van Hilten JJ, Heutink P 2009. Genotypic and phenotypic characteristics of Dutch patients with early onset Parkinson's disease. Mov Disord 24:196-03.
87. Maegley KA, Admiraal SJ, Herschlag D. 1996. Ras-catalyzed hydrolysis of GTP: a new perspective from model studies. Proc Natl Acad Sci USA 93:8160-8166.
88. Marín I. 2006. The Parkinson disease gene LRRK2: evolutionary and structural insights. Mol Biol Evol 23:2423-2433.
89. Masterson LR, Cembran A, Shi L, Veglia G. 2012. Allostery and binding cooperativity of the catalytic subunit of protein kinase a by NMR spectroscopy and molecular dynamics simulations. Adv Protein Chem Struct Biol 87:363-389.
90. Masterson LR, Cheng C, Yu T, Tonelli M, Kornev A, Taylor SS, Veglia G. 2010. Dynamics connect substrate recognition to catalysis in protein kinase A. Nat Chem Biol 6:821-828.
91. Mata IF, Kachergus JM, Taylor JP, Lincoln S, Aasly J, Lynch T, Hulihan MM, Cobb SA, Wu RM, Lu CS, Lahoz C, Wszolek ZK, et al. 2005. Lrrk2 pathogenic substitutions in Parkinson's disease. Neurogenetics 6:171-177.
92. Mata IF, Wedemeyer WJ, Farrer MJ, Taylor JP, Gallo KA. 2006. LRRK2 in Parkinson's disease: protein domains and functional insights. Trends Neurosci 29: 286-293.
93. Matta S, Van Kolen K, da Cunha R, van den Bogaart G, Mandemakers W, Miskiewicz K, De Bock PJ, Morais VA, Vilain S, Haddad D, Swerts J, Chávez-Gutiérrez L, et al. 2012. LRRK2 controls an EndoA phosphorylation cycle in synaptic endocytosis. Neuron 75:1008-1021.
94. Michaely P, Tomchick DR, Machius M, Anderson RG. 2002. Crystal structure of a 12 ANK repeat stack from human ankyrinR. EMBO J 21:6387-6396.
95. Michel F, Soler-Lopez M, Petosa C, Cramer P, Siebenlist U, Müller CW. 2001. Crystal structure of the ankyrin repeat domain of Bcl-3: a unique member of the IkappaB protein family. EMBO J 20:6180-6190.
96. Milburn MV, Tong L, deVos AM, Brünger A, Yamaizumi Z, Nishimura S, Kim SH. 1990. Molecular switch for signal transduction: structural differences between active and inactive forms of protooncogenic ras proteins. Science 247:939-945.
97. Mills RD, Mulhern TD, Cheng HC, Culvenor JG. 2012. Analysis of LRRK2 accessory repeat domains: prediction of repeat length, number and sites of Parkinson's disease mutations. Biochem Soc Trans 40:1086-1089.
98. Morishita EC, Murayama K, Kato-Murayama M, Ishizuka-Katsura Y, Tomabechi Y, Hayashi T, Terada T, Handa N, Shirouzu M, Akiyama T, Yokoyama S 2011. Crystal structures of the armadillo repeat domain of adenomatous polyposis coli and its complex with the tyrosine-rich domain of sam68. Structure 19:1496-1508.
99. Ng CH, Mok SZ, Koh C, Ouyang X, Fivaz ML, Tan EK, Dawson VL, Dawson TM, Yu F, Lim KL. 2009. Parkin protects against LRRK2 G2019S mutant-induced dopaminergic neurodegeneration in Drosophila. J Neurosci 29:11257-11262.
100. Nichols RJ, Dzamko N, Hutti JE, Cantley LC, Deak M, Moran J, Bamborough P, Reith AD, Alessi DR. 2009. Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease. Biochem J 424:47-60.
101. Nichols RJ, Dzamko N, Morrice NA, Campbell DG, Deak M, Ordureau A, Macartney T, Tong Y, Shen J, Prescott AR, Alessi DR 2010. 14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization. Biochem J 430:393-404.
102. Nichols WC, Elsaesser VE, Pankratz N, Pauciulo MW, Marek DK, Halter CA, Rudolph A, Shults CW, Foroud T, Parkinson Study Group PI. 2007. LRRK2 mutation analysis in Parkinson disease families with evidence of linkage to PARK8. Neurology 69:1737-1744.
103. Nichols WC, Pankratz N, Hernandez D, Paisán-Ruíz C, Jain S, Halter CA, Michaels VE, Reed T, Rudolph A, Shults CW, Singleton A, Foroud T, et al. 2005. Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease. Lancet 365:410-412.
104. Nuytemans K, Theuns J, Cruts M, Van Broeckhoven C. 2010. Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update. Hum Mutat 31:763-780.
105. Ohta E, Hasegawa K, Gasser T, Obata F. 2007. Independent occurrence of I2020T mutation in the kinase domain of the leucine rich repeat kinase 2 gene in Japanese and German Parkinson's disease families. Neurosci Lett 417:21-3.
106. Ohta E, Kawakami F, Kubo M, Obata F. 2011a. LRRK2 directly phosphorylates Akt1 as a possible physiological substrate: impairment of the kinase activity by Parkinson's disease-associated mutations. FEBS Lett 585:2165-2170.
107. Ohta E, Kawakami F, Kubo M, Obata F. 2011b. LRRK2 directly phosphorylates Akt1 as a possible physiological substrate: impairment of the kinase activity by Parkinson's disease-associated mutations. FEBS Lett 585:2165-2170.
108. Orenstein SJ, Kuo SH, Tasset I, Arias E, Koga H, Fernandez-Carasa I, Cortes E, Honig LS, Dauer W, Consiglio A, Consiglio A, Raya A, et al. 2013. Interplay of LRRK2 with chaperone-mediated autophagy. Nat Neurosci 16:394-406.
109. Ostrem JM, Peters U, Sos ML, Wells JA, Shokat KM 2013. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 503:548-551.
110. Otomo T, Otomo C, Tomchick DR, Machius M, Rosen MK. 2005. Structural basis of Rho GTPase-mediated activation of the formin mDia1. Mol Cell 18:273-281.
111. Paisán-Ruíz C, Jain S, Evans EW, Gilks WP, Simón J, van der Brug M, López de Munain A, Aparicio S, Gil AM, Khan N, Johnson J, Martinez JR, et al. 2004. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44:595-600.
112. Paisán-Ruíz C, Nath P, Washecka N, Gibbs JR, Singleton AB. 2008. Comprehensive analysis of LRRK2 in publicly available Parkinson's disease cases and neurologically normal controls. Hum Mutat 29:485-490.
113. Pandey N, Fahey MT, Jong YJ, O'Malley KL. 2012. Sequences located within the N-terminus of the PD-linked LRRK2 lead to increased aggregation and attenuation of 6-hydroxydopamine-induced cell death. PLoS One 7:e45149.
114. Parisiadou L, Xie C, Cho HJ, Lin X, Gu XL, Long CX, Lobbestael E, Baekelandt V, Taymans JM, Sun L, Cai H. 2009. Phosphorylation of ezrin/radixin/moesin proteins by LRRK2 promotes the rearrangement of actin cytoskeleton in neuronal morphogenesis. J Neurosci 29:13971-13980.
115. Piccoli G, Condliffe SB, Bauer M, Giesert F, Boldt K, De Astis S, Meixner A, Sarioglu H, Vogt-Weisenhorn DM, Wurst W, Gloeckner CJ, Matteoli M, et al. 2011. LRRK2 controls synaptic vesicle storage and mobilization within the recycling pool. J Neurosci 31:2225-2237.
116. Plowey ED, Cherra SJ, 3rd, Liu YJ, Chu CT. 2008. Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells. J Neurochem 105:1048-1056.
117. Pungaliya PP, Bai Y, Lipinski K, Anand VS, Sen S, Brown EL, Bates B, Reinhart PH, West AB, Hirst WD, Braithwaite SP 2010. Identification and characterization of a leucine-rich repeat kinase 2 (LRRK2) consensus phosphorylation motif. PLoS One 5:e13672.
118. Qing H, Wong W, McGeer EG, McGeer PL. 2009. Lrrk2 phosphorylates alpha synuclein at serine 129: Parkinson disease implications. Biochem Biophys Res Commun 387:149-152.
119. Ramsden N, Perrin J, Ren Z, Lee BD, Zinn N, Dawson VL, Tam D, Bova M, Lang M, Drewes G, Bantscheff M, Bard F, et al. 2011. Chemoproteomics-based design of potent LRRK2-selective lead compounds that attenuate Parkinson's disease-related toxicity in human neurons. ACS Chem Biol 6:1021-1028.
120. Ren Y, Seo HS, Blobel G, Hoelz A. 2010. Structural and functional analysis of the interaction between the nucleoporin Nup98 and the mRNA export factor Rae1. Proc Natl Acad Sci USA 107:10406-10411.
121. Ross OA, Soto-Ortolaza AI, Heckman MG, Aasly JO, Abahuni N, Annesi G, Bacon JA, Bardien S, Bozi M, Brice A, Brighina L, Van Broeckhoven C, et al. 2011. Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case-control study. Lancet Neurol 10:898-908.
122. Rudenko IN, Kaganovich A, Hauser DN, Beylina A, Chia R, Ding J, Maric D, Jaffe H, Cookson MR. 2012. The G2385R variant of leucine-rich repeat kinase 2 associated with Parkinson's disease is a partial loss-of-function mutation. Biochem J 446:99-111.
123. Russo AA, Tong L, Lee JO, Jeffrey PD, Pavletich NP. 1998. Structural basis for inhibition of the cyclin-dependent kinase Cdk6 by the tumour suppressor p16INK4a. Nature 395:237-243.
124. Scott PG, Dodd CM, Bergmann EM, Sheehan JK, Bishop PN. 2006. Crystal structure of the biglycan dimer and evidence that dimerization is essential for folding and stability of class I small leucine-rich repeat proteoglycans. J Biol Chem 281:13324-13332.
125. Scrima A, Konícková R, Czyzewski BK, Kawasaki Y, Jeffrey PD, Groisman R, Nakatani Y, Iwai S, Pavletich NP, Thomä NH. 2008. Structural basis of UV DNA-damage recognition by the DDB1-DDB2 complex. Cell 135:1213-1223.
126. Seewald MJ, Körner C, Wittinghofer A, Vetter IR. 2002. RanGAP mediates GTP hydrolysis without an arginine finger. Nature 415:662-666.
127. Sen S, Webber PJ, West AB. 2009. Dependence of leucine-rich repeat kinase 2 (LRRK2) kinase activity on dimerization. J Biol Chem 284:36346-36356.
128. Sheng D, Qu D, Kwok KH, Ng SS, Lim AY, Aw SS, Lee CW, Sung WK, Tan EK, Lufkin T, Jesuthasan S, Sinnakaruppan M, et al. 2010. Deletion of the WD40 domain of LRRK2 in Zebrafish causes Parkinsonism-like loss of neurons and locomotive defect. PLoS Genet 6:e1000914.
129. Sheng Z, Zhang S, Bustos D, Kleinheinz T, Le Pichon CE, Dominguez SL, Solanoy HO, Drummond J, Zhang X, Ding X, Cai F, Song Q, et al. 2012. Ser1292 autophosphorylation is an indicator of LRRK2 kinase activity and contributes to the cellular effects of PD mutations. Sci Transl Med 4:164ra161.
130. Shin N, Jeong H, Kwon J, Heo HY, Kwon JJ, Yun HJ, Kim CH, Han BS, Tong Y, Shen J, Hatano T, Hattori N, et al. 2008. LRRK2 regulates synaptic vesicle endocytosis. Exp Cell Res 314:2055-2065.
131. Sim CH, Lio DS, Mok SS, Masters CL, Hill AF, Culvenor JG, Cheng HC. 2006. C-terminal truncation and Parkinson's disease-associated mutations down-regulate the protein serine/threonine kinase activity of PTEN-induced kinase-1. Hum Mol Genet 15:3251-3326.
132. Skipper L, Shen H, Chua E, Bonnard C, Kolatkar P, Tan LC, Jamora RD, Puvan K, Puong KY, Zhao Y Pavanni, R., Wong, MC. et al. 2005. Analysis of LRRK2 functional domains in nondominant Parkinson disease. Neurology 65:1319-1321.
133. Skowyra D, Craig KL, Tyers M, Elledge SJ, Harper JW. 1997. F-box proteins are receptors that recruit phosphorylated substrates to the SCF ubiquitin-ligase complex. Cell 91:209-219.
134. Smith WW, Pei Z, Jiang H, Dawson VL, Dawson TM, Ross CA. 2006a. Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat Neurosci 9:1231-1233.
135. Smith WW, Pei Z, Jiang H, Dawson VL, Dawson TM, Ross CA. 2006b. Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat Neurosci 9:1231-1233.
136. Smith WW, Pei Z, Jiang H, Dawson VL, Dawson TM, Ross CA. 2006c. Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat Neurosci 9:1231-1233.
137. Song JJ, Garlick JD, Kingston RE. 2008. Structural basis of histone H4 recognition by p55. Genes Dev 22:1313-1318.
138. Stafa K, Trancikova A, Webber PJ, Glauser L, West AB, Moore DJ. 2012. GTPase activity and neuronal toxicity of Parkinson's disease-associated LRRK2 is regulated by ArfGAP1. PLoS Genet 8:e1002526.
139. Tan EK, Skipper LM. 2007. Pathogenic mutations in Parkinson disease. Hum Mutat 28:641-653.
140. Tanaka N, Arai J, Inokuchi N, Koyama T, Ohgi K, Irie M, Nakamura KT. 2000. Crystal structure of a plant ribonuclease, RNase LE. J Mol Biol 298:859-873.
141. Tanaka N, Nakanishi M, Kusakabe Y, Goto Y, Kitade Y, Nakamura KT. 2004. Structural basis for recognition of 2', 5'-linked oligoadenylates by human ribonuclease L. EMBO J 23:3929-3938.
142. Tanaka N, Nakanishi M, Kusakabe Y, Goto Y, Kitade Y, Nakamura KT. 2005. Molecular basis for recognition of 2', 5'-linked oligoadenylates by the N-terminal ankyrin repeat domain of human ribonuclease L. Nucleic Acids Symp Ser (Oxf) 49:323-324.
143. Taymans JM, Vancraenenbroeck R, Ollikainen P, Beilina A, Lobbestael E, De Maeyer M, Baekelandt V, Cookson MR. 2011. LRRK2 kinase activity is dependent on LRRK2 GTP binding capacity but independent of LRRK2 GTP binding. PLoS One 6:e23207.
144. Tong Y, Pisani A, Martella G, Karouani M, Yamaguchi H, Pothos EN, Shen J. 2009. R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice. Proc Natl Acad Sci USA 106:14622-14627.
145. Turk BE. 2008. Understanding and exploiting substrate recognition by protein kinases. Curr Opin Chem Biol 12:4-10.
146. Ubersax JA, Ferrell JE, Jr. 2007. Mechanisms of specificity in protein phosphorylation. Nat Rev Mol Cell Biol 8:530-541.
147. van Egmond WN, Kortholt A, Plak K, Bosgraaf L, Bosgraaf S, Keizer-Gunnink I, van Haastert PJ. 2008. Intramolecular activation mechanism of the Dictyostelium LRRK2 homolog Roco protein GbpC. J Biol Chem 283:30412-30420.
148. Vancraenenbroeck R, Lobbestael E, Weeks SD, Strelkov SV, Baekelandt V, Taymans JM, De Maeyer M. 2012. Expression, purification and preliminary biochemical and structural characterization of the leucine rich repeat namesake domain of leucine rich repeat kinase 2. Biochim Biophys Acta 1824:450-460.
149. West AB, Moore DJ, Biskup S, Bugayenko A, Smith WW, Ross CA, Dawson VL, Dawson TM. 2005. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci USA 102:16842-16847.
150. West AB, Moore DJ, Choi C, Andrabi SA, Li X, Dikeman D, Biskup S, Zhang Z, Lim KL, Dawson VL, Dawson TM. 2007. Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum Mol Genet 16:223-232.
151. White MA, Nicolette C, Minden A, Polverino A, Van Aelst L, Karin M, Wigler MH. 1995. Multiple Ras functions can contribute to mammalian cell transformation. Cell 80:533-541.
152. Wittinghofer A, Vetter IR. 2011. Structure-function relationships of the G domain, a canonical switch motif. Annu Rev Biochem 80:943-971.
153. Xia Y, Wu Z, Su B, Murray B, Karin 1998. JNKK1 organizes a MAP kinase module through specific and sequential interactions with upstream and downstream components mediated by its amino-terminal extension. Genes Dev 12:3369-3381.
154. Xiong Y, Coombes CE, Kilaru A, Li X, Gitler AD, Bowers WJ, Dawson VL, Dawson TM, Moore DJ. 2010. GTPase activity plays a key role in the pathobiology of LRRK2. PLoS Genet 6:e1000902.
155. Xiong Y, Dawson VL, Dawson TM. 2012a. LRRK2 GTPase dysfunction in the pathogenesis of Parkinson's disease. Biochem Soc Trans 40:1074-1079.
156. Xiong Y, Yuan C, Chen R, Dawson TM, Dawson VL. 2012b. ArfGAP1 is a GTPase activating protein for LRRK2: reciprocal regulation of ArfGAP1 by LRRK2. J Neurosci 32:3877-3886.
157. Xiromerisiou G, Hadjigeorgiou GM, Gourbali V, Johnson J, Papakonstantinou I, Papadimitriou A, Singleton AB. 2007. Screening for SNCA and LRRK2 mutations in Greek sporadic and autosomal dominant Parkinson's disease: identification of two novel LRRK2 variants. Eur J Neurol 14:7-11.
158. Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, Kachergus J, Hulihan M, Uitti RJ, Calne DB, Stoessl AJ, Pfeiffer RF, et al. 2004. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44:601-607.
159. Zuccotto F, Ardini E, Casale E, Angiolini M. 2010. Through the "gatekeeper door": exploiting the active kinase conformation. J Med Chem 53:2681-2694.